Jo Ann Horowitz is a seasoned physician and consultant, leveraging her extensive expertise in hematology and oncology to drive innovation in drug development through her firm, J A Horowitz Clinical Solutions, LLC. With a robust background in all phases of clinical research, Jo Ann has...
Jo Ann Horowitz is a seasoned physician and consultant, leveraging her extensive expertise in hematology and oncology to drive innovation in drug development through her firm, J A Horowitz Clinical Solutions, LLC. With a robust background in all phases of clinical research, Jo Ann has successfully led multidisciplinary teams in the pharmaceutical industry, navigating the complexities of clinical trials and regulatory pathways to achieve drug approvals. Her current role as a self-employed consultant allows her to provide invaluable insights and strategic guidance to pharmaceutical and biotechnology companies, particularly those in the start-up phase seeking to develop transformative therapies with novel mechanisms of action.
Jo Ann's key projects often revolve around early and late-phase clinical development programs, where she applies her deep understanding of regulatory requirements and U.S. Food and Drug Administration (FDA) processes to facilitate New Drug Application (NDA) filings. Her experience encompasses targeted therapies and gene therapy, positioning her as a thought leader in the rapidly evolving landscape of life sciences. By collaborating closely with regulatory and marketing teams, she crafts coordinated strategies that enhance the likelihood of successful product launches and market penetration.
In addition to her clinical development expertise, Jo Ann is adept in medical writing and the use of Clinical Trial Management Systems (CTMS), ensuring that all documentation meets stringent regulatory standards. Her leadership style fosters collaboration and innovation, making her a sought-after consultant for companies aiming to navigate the complexities of drug development while maximizing their potential for success in the competitive pharmaceutical arena. Through her work, Jo Ann continues to make significant contributions to the advancement of hematology and oncology therapies, ultimately improving patient outcomes and transforming lives.
